Greensboro, North Carolina — According to state and local development sources, ProKidney plans to invest $485,000,000.00 to build out 210,000 square feet of new space in Greensboro. The company plans to occupy the new space at 73 Business Center in Greensboro, on or about November 1, 2026. According to the company website ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidneys lead product candidate, REACT (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b – 4, is a key target for REACT therapy. REACT has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.

To learn more about ProKidney, visit http://prokidney.com/

Company Contact:
Tim Bertram, Chief Executive Officer
tim.bertram@prokidney.com
336-999-7028

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.